This paper proposes a new framework of design and analysis of phase III randomized clinical trials with embedded DNA microarrays toward personalized or predictive medicine. The proposed framework allows randomized clinical trials to assess treatment efficacy for a patient population in a manner that takes into consideration the heterogeneity in patients' responsiveness to treatment on survival outcomes, and also predicts patient-level survival curves and treatment effects for individual patients. 
STATEMENT OF TRANSLATIONAL RELEVANCE:
This paper proposes a new framework of design and analysis of phase III randomized clinical trials with embedded DNA microarrays toward personalized or predictive medicine. The proposed framework allows randomized clinical trials to assess treatment efficacy for a patient population in a manner that takes into consideration the heterogeneity in patients' responsiveness to treatment on survival outcomes, and also predicts patient-level survival curves and treatment effects for individual patients.
Through providing the new framework for developing and validating continuous genomic signatures in randomized trials, this paper could contribute to accelerating modern clinical studies toward predictive medicine.
This paper also provides an interesting illustration of the new framework, indicating one of the first successes in exploring predictive signatures that predict treatment efficacy on overall survival using microarray gene expression data in phase III randomized trials.
This would encourage clinical investigators to plan for collection of genomic data in designing future randomized clinical trials. 4 survival curves were developed to predict survival distributions of individual future patients as a function of whether or not they are treated with thalidomide and with regard to their baseline prognostic and predictive signature indices.
Conclusion:
The proposed framework represents an important step towards reliable predictive medicine. It provides an internally validated mechanism for using randomized clinical trials to assess treatment efficacy for a patient population in a manner that takes into consideration the heterogeneity in patients' responsiveness to treatment. It also provides cross-validated patient-level survival curves that can be used for selecting treatments for future patients.
Introduction
Advances in our understanding of the biology of human cancers have revealed substantial molecular heterogeneity of most conventional histologic diagnoses. In treating cancer patients, this implies that only a subset of treated patients are likely to benefit from a given therapy. This is particularly relevant for molecularly targeted drugs (1-3). As such, there is a substantial growing need for developing a diagnostic test to predict responsiveness of a given treatment for individual patients. To this end, basic research often suggests a panel of candidate predictive markers. Genomic technologies such as microarrays have provided powerful tools for developing genomic signatures (diagnostic tests) based on genome-wide screening. Ideally, the diagnostic test would be developed before initiating the definitive phase III trial that evaluates its effectiveness in distinguishing patients who benefit from a new treatment from those who do not with regard to clinical endpoints such as survival or disease-free survival (4) . However, this is difficult because of the complexity of signaling pathways and the inherent difficulty in developing reliable diagnostic tests for clinical endpoints using early phase II data.
One approach to address this issue, where a signature to identify responsive patients is unavailable, is to design and analyze the randomized phase III trial in such a way that both developing a genomic signature and testing treatment efficacy based on the developed signature is possible and performed validly. The adaptive signature designs (ASDs) have been proposed for this purpose (5, 6 ) (see Appendix A).
A genomic signature is usually developed as a composite score integrating the status or values of multiple component genes. Such signatures are continuously valued and represent varying treatment effects among patients (7) , reflecting the complexity of disease biology. For developing a diagnostic test, one conventional framework is to 6 define responsive and non-responsive patients by invoking a thresholding of the continuous score (i.e., patients whose scores are higher or smaller than a threshold are defined as responsive patients) as done in the ASDs (5, 6) . However, in this framework, information regarding varying treatment effects among responsive patients would be lost. This can be a concern for plausible situations where treatment selection is affected by many factors, including adverse effects, cost of treatment, and patient's preference, and thus the size of treatment effect that leads to a patient's selecting the treatment can differ among patients. This suggests the need for another framework that presents the treatment effect as a function of the continuous genomic signature as a more relevant diagnostic tool for predictive medicine.
In this article, we consider this framework and propose a new methodology for developing and validating genomic signatures in randomized trials, through estimating the underlying profile of the variation of treatment effects as a function of continuous genomic signatures. Based on an estimate of this function, we can provide a cross-validation based test of treatment efficacy for the patient population, and also provide cross-validated patient-level survival curves and treatment effects for use in treatment decisions for individual patients. The motivating example is a phase III trial for assessing whether the addition of thalidomide improves survival for patients with multiple myeloma undergoing high-dose therapy (8) (9) . Fig. 1 shows a small survival difference between the two treatment arms (thalidomide and no thalidomide) for the subset of patients with genomic data in the trial. This small average effect may reflect the heterogeneity in the effects of thalidomide. By applying our framework to the data of this trial, we can estimate the profile of treatment effects as a function of the genomic signature (with a normalized range from zero to one), as shown in Fig. 2 . This allows us 7 to predict the treatment effect for any individual patient. Based on the estimated treatment effects function, the treatment effect for the overall population and it's heterogeneity can be assessed. Furthermore, our framework allows prediction of patient-level survival curves for each treatment for any subset of patients with various degrees of responsiveness to treatments and various degrees of baseline risks, represented by the predictive and prognostic signatures, as shown in Fig. 3 . Such prediction curves can serve as a basic diagnostic tool for selecting appropriate treatments for future patients.
Methods
We consider a randomized trial to compare an experimental (E) and control treatment (C). We suppose that pretreatment genomic data for signature development is available for a total of n patients. To be specific, we suppose that pretreatment expression levels for a total of G genes are measured using microarrays for each patient, although other types of genomic data such as single nucleotide polymorphism genotyping, copy number profiling, and proteomic profiling data can be utilized similarly.
There are four components in our framework: 1) Development of a continuous signature score, 2) Estimation of the treatment effects as a function of the developed score, 3) Test of the strong null hypothesis that the treatment has no effect on any patients, 4) Prediction of patient-level survival curves for future patients.
The statistical models and procedures used in all the components must be pre-specified. The last component is a step for developing a basic diagnostic tool to aid selecting appropriate treatments for individual future patients, which is different from the purpose of assessing treatment efficacy for a patient population.
Development of Genomic Signature Score
Because the genomic signature is to predict treatment effects for individual patients, we consider a framework of prediction analysis and apply complete K-fold cross-validation (CV) as in the cross-validated adaptive signature design because it is more efficient than the split-sample approach (6) (see Appendix A). In the K-fold CV, the trial population is split into K roughly equal-sized parts. Patient allocation into the K parts must be prospectively defined. For the k-th part, a genomic signature is developed using the data from the other K -1 parts as a training set, and it is applied to the k-th part as a test set (k = 1, …, K). In each fold of CV, the development of the genomic signature is typically composed of selection of predictive gene features from scratch and building of a signature scoring using the selected gene features for the training set (see Appendix B). Without loss of generality, we suppose that the signature score is developed such that, for a patient with a low value of the developed score, the survival probability when receiving E is predicted to be higher than that when receiving C; as such, this patient is predicted to be responsive to E. A large variety of algorithms for developing such scores could be envisaged. The compound covariates predictor is one of the simple, but effective algorithms for high-dimensional genomic data (see Appendix B). After developing a signature scoring function using the training set, we apply it to compute predicted scores for all patients in the test set (denoted by U i in 9 Appendix B). The value of the predicted score for each patient in the test set is normalized as a quantile (or percentile) value based on the score distribution in the training set.
In each fold of the CV, it is critical that all aspects of the signature development, including selection of gene features, are re-performed (10, 11) . When selection of gene features and/or prediction models to develop the signature are optimized based on cross-validated predictive accuracy, the optimization process should be included in the K-fold CV with application of a nested inner loop of K-fold CV (12, 13) .
After completion of the K-fold CV, we have the predicted (quantile) scores for all n patients. We denote the score for patient i as S i ∈ (0, 1) (i = 1, …, n). Note that, because S i is a quantile measure, it is essentially continuously valued. Again, for patients with lower values of S i , the survival probabilities when receiving E are predicted to be higher than those when receiving C.
Estimation of the treatment effects function
We estimate the treatment effects as a function of S i , Ψ(s) say. As a basic measure of treatment effects, we consider a logarithm of the hazard ratio between the two treatment arms under the proportional hazards assumption that the hazard ratio is constant over time. Specifically, for a patient with the score value S = s, Ψ(s) = (the log hazard for a patient with S = s when receiving E) -(the log hazard for a patient with S = s when receiving C) [1] represents the treatment effect for that patient. We assume the multivariate Cox proportional hazards model, 
where r i is the treatment assignment indicator such that r i = 1 if patient i is assigned to treatment E and r i = 0 otherwise. Here the functions f 2 and f 3 capture the main effects of S and the interactions between S and r, respectively. These effects can be non-linear, but should be monotonic in S, because the score S has been developed such that its lower value represents greater responsiveness to E, on the basis of commonly used linear models in selection of gene features and development of the signature score S (See Appendix B). One simple specification to have monotonic effects for S is to use the fractional polynomials (14) (see Appendix C). The model [2] is fitted by maximum (partial) likelihood. Under the model [2] , the treatment effects function Ψ will be expressed as,
Under the specification of monotonic effects for the interaction f 3 , the estimated function, Ψ , will also be monotone. In particular, if the developed signature score S is truly effective in predicting the effect of E, a non-decreasing shape of Ψ is expected We can perform a test of treatment efficacy for a patient population based on the estimated treatment effects function Ψ . Because our models incorporate varying treatment effects on individual patients, it is natural to consider the strong null hypothesis, H 0 , that the treatment has no effect on any patients. Under H 0 , the null distribution of Ψ and p-values can be obtained by a permutation method that randomly permutes treatment labels. For permutation datasets, the entire CV procedure, including the signature development and the estimation of Ψ, is repeated to obtain a null distribution of Ψ . We propose to use an average absolute effect size over the entire patient population as the test statistic (see Appendix D). It corresponds to a two-sided alternative hypothesis to detect treatment effects in both directions where the treatment E (C) is superior to C (E). Another approach is, like in the second stage of the ASDs (5, 6) (see Appendix A), to test treatment effects for a subset of patients with
who are predicted to be responsive to E. We can consider an average treatment effect over the responsive patients as the test statistic for a one-sided test to detect treatment effects in the direction where the treatment E is superior to C (see Appendix D).
Prediction of patient-level survival curves
Although the estimation of the treatment effects function, Ψ(s), provides direct information regarding the sizes of treatment effects for individual patients in terms of the (logarithm of) hazard ratio, information regarding the survival curves when individual patients receive either one of the two treatments would be more relevant. The patient-level survival curves can be predicted on the basis of the estimates of the baseline hazard function and regression coefficients by fitting the multivariate Cox proportional hazards model [2] . However, this model, which can work well for where the function f 4 represents an effect of a prognostic index w i . Note that, under the model [4] , we have the same form of the treatment effects function [3] with that under the model [2] , but the effects β 1 and f 3 are now interpreted with the use of the prognostic index w (or after adjustment for the prognostic term f 4 ).
The prognostic index, w, can be established based on clinical prognostic factors.
However, recent prognostic studies have demonstrated improvement of the accuracy of prognostic prediction by incorporating genomic signatures (15-17). Because large-scale phase III trials with pretreatment genomic data also provide a precious chance for developing reliable prognostic signatures, in addition to reliable predictive signatures, co-development of them would be warranted. Our methodology can be easily extended in this direction. Within the K-fold CV, we develop a prognostic signature score, independently of developing the predictive signature score, S, through correlating genomic data with survival outcomes without reference to treatment assignment. An algorithm similar to that for developing the predictive signature is given in Appendix B.
At each step of the K-fold CV, we can fit a multivariate Cox model with the developed genomic signature score and clinical prognostic factors as covariates to obtain a composite prognostic signature. A quantile score can also be developed for the prognostic signature. Then, the developed (quantile) prognostic score is used for w in the model [4] . patient-level survival curve or survival rate at a given time point for each treatment. We then compare the predicted survival curve when receiving E and that when receiving C to assess the benefit of receiving E for that patient.
Finally, we regard the entire n patients in the clinical trial as a training set and apply the entire procedure. That is, we develop predictive and prognostic scoring functions and compute scores for all n patients. When feature selection and/or prediction models are optimized in the prior K-fold CV, we invoke a new session of K-fold CV for n patients to determine optimal values of the tuning parameters using the same optimization procedure, and then compute scores at these values for n patients.
The empirical distributions of those scores serve as reference distributions. For any new patient, the scoring functions are used to compute predictive and prognostic scores which are then normalized using the reference distributions. For the new patient, we then assess the expected treatment effect by plugging these values into the estimated treatment effects function, Ψ , obtained in the cross-validated prediction analysis. From [4] one can also compute the predicted survival curves for the new patient under each treatment based on the cross-validated prediction analysis.
Results
A large-scale randomized phase III trial was conducted to assess whether the addition of thalidomide, which has activity against advanced and refractory multiple myeloma, improves survival in the up-front management of patients with multiple myeloma undergoing melphalan-based tandem transplantation (8, 9) . Despite significantly higher complete response rate and superior event-free survival among patients randomized to thalidomide, compared with the control patients with no thalidomide, overall survival (OS) was similar between treatment groups at the time of first publication, with a median follow-up of 42 months (8) , although, with longer follow-up of 72 months, a tendency of long-term effect of thalidomide on OS was observed (9) . As another unique feature of this phase III trial, pretreatment RNA from highly purified plasma cells was applied to Affymetrix U133Plus2.0 microarrays for 351 patients, out of 668 randomized patients. Because the efficacy of thalidomide on OS has been relatively uncertain, we performed a predictive analysis for OS using the data with at a median follow-up of 72 months for 351 patients with microarray gene expression data. Fig. 1 shows an OS curve for 351 patients by treatment arm (175 with thalidomide and 176 with no thalidomide (control)).
For each of 54,675 gene features on the microarray, we standardized gene expression levels after normalization to have mean zero and standard deviation one across all 351 patients. We first developed the predictive signature score, S, and the prognostic signature score, W, using a 5-fold CV. For the training set, we screened predictive genes using the significance level of 0.001 for a score test for no interaction between the gene feature and treatment and developed a compound covariates predictor (see Appendix B). Similarly, but independently, we screened prognostic genes using the significance level of 0.001 for a score test for no association of the gene feature and OS developed a compound covariates predictor (see Appendix B). We then obtained the predicted (quantile) signature scores S and W for the test set. After the completion of the 5-fold CV, we had obtained the predicted values of these scores for all 351 patients.
We fit the multivariate Cox proportional hazards model with both S and W in [4] for the entire patient cohort. We specified linear terms for the main effects of S and W, We performed a test of treatment efficacy for the subset of the patient population predicted to benefit from thalidomide based on ) ( s Ψ . Because the interest in this randomized trial was to assess improvement in survival by adding thalidomide for patients with high-dose therapies, compared with the control arm with no thalidomide, it is reasonable to test treatment efficacy for a subset of patients who are considered to be responsive to thalidomide using the one-sided test statistic (see [A4] in Appendix D).
The observed value of the test statistic was -0.47 in log hazard ratio (0.62 in hazard ratio). The p-value obtained from 2,000 permutations was 0.019, which is significant if our test is employed for a significance level 2% at the second stage of cross-validated adaptive signature design (6) (Appendix A). For reference, the permutation-based Generally, even for the same level of the predictive score, S, the effect size of thalidomide was larger (larger absolute difference in the predicted survival rate under each treatment) for patients with poor prognosis (larger W). For example, for patients with S = 0.1, the difference in the predicted survival rate was 17.9% for W = 0.1, while it was 27.8% for W = 0.9 (see also Fig. 3a and b) . proposed method can detect treatment effects for a subset of responsive patients, uncertainty in identifying the responsive subset based on ) ( s Ψ (due to possible model misspecification and random variation) may limit confidence in labeling of the new treatment for the identified patient subset (i.e., ) ( s Ψ < 0). The proposed method, however, can provide useful information for designing a second confirmatory trial, possibly with a targeted or enrichment design with small sample sizes, especially when there is no overall treatment effect for the entire population.
Our methodology can also be useful even if the overall average treatment effect is significant. In order to avoid over-treatment of the population, it is useful to identify patient subsets who receive large, small or no benefits from the treatment and to predict patient-level survival curves to aid selecting treatment for individual patients. Provided that some conditions are met (19) , our methodology could also be applied to genomic data from past randomized trials to analyze the heterogeneity in treatment effects over the study population and to develop diagnostic tools for established treatments.
Confidence intervals for the treatment effects function and patient-level survival curves are particularly important both in assessing the heterogeneity of treatment effects across patients and in developing diagnostic tools for individual patients. Construction of these intervals via resampling methods is another subject for future research.
Lastly, for utilizing our framework, it is essential to plan for collection of genomic data in designing randomized clinical trials. The rapid development of high-throughput technologies, which has reduced the cost of microarrays and exome sequencing, and 
Appendix A: Adaptive Signature Designs (ASDs)
These designs first test the overall treatment effects for the entire study population using a significant level α 1 (e.g., 0.03), out of the overall type I error rate 0.05. If it is not significant, these designs proceed to the second stage. A genomic classifier is developed for a portion of samples (training set) and the treatment efficacy for the patient subset classified as "responsive" to the new treatment is tested at significance level 0.05 -α 1 (e.g., 0.02) for the rest samples (test set). The second stage can be based on split-sample (5) or cross-validation (6). The latter, called the cross-validated adaptive signature design, is expected to be more efficient because it maximizes the portion of samples contributing to the signature development (6). 
Appendix B: Algorithms for Developing Genomic Signatures

Selection of predictive gene features
Compound covariates predictor for developing genomic signatures
To cope with the interaction effects of a number of predictive gene features, we consider a composite score. Specifically, for patient i,
where Ω is the set of selected genes in the step 1 and z g is a standardized test statistic of the interaction test for gene g obtained from the training set. This is the compound covariates predictor (21) (22) (23) . If the patient i belongs to the test set, the value of score U i is regarded as a predicted value. Smaller values of U i correspond to greater chance of benefitting from E relative to C.
Development of Prognostic Signatures
Screening of prognostic genes is typically based on a score (logrank) test or Wald test derived from a univariate Cox regression that correlates a single gene with survival outcome (24) , without regard to treatment assignment. The test is predicated on the definition of prognostic genes that have similar effects on survival, irrespective of which treatment is received. There are a large variety of algorithms for developing prognostic signatures (24) . Again, the compound covariates predictor is one of simple, but effective algorithms for high-dimensional genomic data, where the standardized test statistic from a univariate Cox regression is used for z g in [A2] for a set of selected prognostic genes Ω. 
Appendix C: Fractional Polynomials
Appendix D: Test Statistics and P-values
As a test statistic for a two-sided alternative hypothesis to detect treatment effects in both directions where the treatment E (C) is superior to C (E), we propose to use the following test statistic,
which represents a summation of absolute effect sizes, or equivalently, an average absolute effect size over the entire patient population. Another approach is, like in the second stage of the ASDs (5, 6) (see Appendix A), to test treatment effects for a subset of patients with ) ( s Ψ < 0, who are predicted to be responsive to E. Let I be a collection of s that satisfies ) ( s Ψ < 0, which represents a group of responsive patients to E, and L be the size or length of I, which represents the size of the group of responsive patients. Then, as the counterpart of T, we can consider a one-sided test statistic,
which represents an average treatment effect over the responsive patients.
In calculating p-values of the two-sided statistic T using the permutation method,
we count the number of permutations with the values of T are equal or larger than the observed value of T. For the one-sided statistic T R , we count the number of permutations with the values of T R are equal or less than the observed value of T R . 
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